News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 73–108
- Matches
- 329
- Sources here
- 22
- Companies here
- 11
Active search
329 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Becton Dickinson has seen its analyst fair value estimate move from US$181.23 to US$189.58, signaling a refreshed price target framework that investors are watching …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%Why Becton Dickinson (BDX) Is Up 6.8% After Q3 Beat And GLP-1 Delivery Partnerships
Becton, Dickinson and Company recently reported third-quarter fiscal 2026 results, with sales rising to US$4,983 million while net income fell to US$377 million, and modestly raised its full-year outlook for low single-digit plus GAAP revenue growth. Alongside these earnings, BD highlighted strong momentum in …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%Becton, Dickinson and Company (NYSE:BDX) Given New $204.00 Price Target at Citigroup
Citigroup has raised its price target for Becton, Dickinson and Company (NYSE:BDX) to $204.00 from $198.00, maintaining a "buy" rating, which implies a potential upside of 15.56%. This adjustment follows Becton Dickinson's exceeding quarterly expectations with adjusted EPS of $3.23 and revenue of $4.98 …
Royal Bank Of Canada Upgrades Becton, Dickinson and Company (NYSE:BDX) to Hold
Royal Bank of Canada has upgraded Becton, Dickinson and Company (NYSE:BDX) to a "hold" rating. The company recently reported strong quarterly results, with revenue and EPS beating analyst estimates, and has raised its fiscal 2026 EPS guidance. Despite positive sentiment from some analysts and …
Rhinebeck Bancorp Inc (RBKB) Stock News Today
This article provides current stock information for Rhinebeck Bancorp Inc (RBKB), including its recent trading price, market capitalization, and P/E ratio. It indicates that more news and updates on RBKB are expected soon. The page serves as a hub for financial data, news, and …
Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and ...
This article first appeared on GuruFocus. Revenue: $5 billion, up 4.4% on an FX-neutral basis. Adjusted Operating Margin: 24.9%, down 130 basis points versus the prior year. Adjusted Gross Margin: 54.3%, down 100 basis points versus the prior year. Adjusted EPS: $3.23, up 4.9%. …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%EMBC Deadline: EMBC Investors with Losses in Excess of $100K Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, of the August 17, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Embecta made false and …
Becton Dickinson (BDX) Stock Shrugs Off Profit Strength As Tariffs Bite
Becton Dickinson (BDX) stock saw a minimal slip of 0.1% despite strong adjusted earnings per share of US$3.23 and a solid operating margin of 24.9% in its Q3 2026 earnings report. While the company's "New BD" strategy is showing positive signs like FX-neutral revenue …
Embecta forecasts $1.80-$1.90 FY2026 adjusted EPS while raising adjusted operating margin to 23.5%-24%
Earnings Call Insights: Embecta (EMBC) Q3 fiscal 2026 MANAGEMENT VIEW * "During the third quarter, Embecta generated total revenue of approximately $272 million" and "on a sequential basis, our third quarter financial performance improved significantly with revenue increasing approximately $50 million" (President, CEO & …
Embecta Corp. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:EMBC) 2026-08-07
Embecta Corp (EMBC) reported a strong sequential recovery in Q3 fiscal 2026, with revenue increasing by approximately $50 million and adjusted operating income rising by about $21 million compared to Q2. The company raised its fiscal 2026 adjusted operating margin guidance to 23.5%-24% and …
EQUITY ACTION ALERT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC)
Faruqi & Faruqi, LLP is reminding Embecta (EMBC) investors of the August 17, 2026 deadline to seek lead plaintiff status in a securities class action lawsuit. The lawsuit alleges that Embecta made misleading statements regarding its financial guidance, particularly its pen needle business, which …
Becton, Dickinson's Fiscal Q3 Results Show Progress Amid Major Headwinds, RBC Says
RBC Capital Markets highlighted Becton, Dickinson and Company's fiscal third-quarter results as indicative of progress despite significant economic challenges. The firm acknowledged the company's efforts in managing headwinds like foreign exchange and inflation, which were largely offset by strong operational performance and effective cost …
Embecta Corp (EMBC) (Q3 2026) Earnings Call Highlights: Strong Sequential Recovery and Raised ...
Embecta Corp (EMBC) reported a strong sequential recovery in Q3 fiscal 2026, with revenue increasing by approximately $50 million and adjusted operating income rising by about $21 million compared to Q2. The company raised its fiscal 2026 adjusted operating margin guidance to 23.5%-24% and …
EMBECTA DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Embecta Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action – EMBC
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the “Class Period”), of the important August …
Embecta Corp. (Nasdaq: EMBC) Q3 2026 profit slides on revenue decline
Embecta Corp. (EMBC) reported a significant decline in Q3 2026 profits and revenue, with net income falling 53.6% to $21.1 million and revenue decreasing by 8.1% to $271.7 million, largely due to lower pricing and volumes. The company completed the $208.0 million acquisition of …
Embecta Corp. 2026: Revenue $271.7M, EPS $0.36— 10-Q Summary
Embecta Corp. reported its 2026 quarter results with revenue of $271.7 million and diluted EPS of $0.36, marking a significant decrease from the prior year. The revenue decline was attributed to lower volume and pricing pressure, despite the acquisition of Owen Mumford. The company …
embecta Reports Third Quarter Fiscal 2026 Financial Results
Embecta Corp. announced its third-quarter fiscal 2026 financial results on August 7, 2026, holding a conference call and live webcast for analysts and investors. The company is transitioning from focusing solely on insulin delivery to becoming a broader medical supplies company. While the official …
Embecta reports Q3 FY2026 revenue $271.7M, GAAP net income $21.1M; raises adjusted EPS guidance
Embecta (EMBC) reported its Q3 FY2026 financial results, achieving revenues of $271.7 million and a GAAP net income of $21.1 million. The company posted adjusted diluted EPS of $0.56 and has raised its full-year adjusted operating margin and adjusted EPS guidance, while reaffirming full-year …
embecta Sets Sept. 15 Payment Date for $0.01 Cash Dividend
embecta (Nasdaq: EMBC) has announced that its Board of Directors declared a quarterly cash dividend of $0.01 per share. The dividend is payable on September 15, 2026, to stockholders of record as of August 27, 2026. Following this news, EMBC's stock gained 27.29%, indicating …
embecta Announces Quarterly Cash Dividend
Embecta Corp. (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 per share. The dividend is payable on September 15, 2026, to stockholders of record as of August 27, 2026. Embecta is a global medical supplies company focused on insulin delivery and other …
Becton, Dickinson and Company Stock 12‑Month Price Target Raised to $187.18, Implies 10% Upside
Becton, Dickinson and Company's (BDX) average 12-month price target has been increased to $187.18 by 11 analysts, up from $178.2, implying a 10% potential upside from its Aug. 5 closing price. The consensus rating for the stock remains a "Buy" among 16 analysts, with …
Becton Dickinson raises lower end of annual profit forecast on drug delivery devices strength
Becton Dickinson raised the lower end of its annual adjusted profit forecast for 2026 after exceeding Wall Street estimates for its third-quarter profit and revenue. The company attributed this performance to strong demand for its drug-delivery devices and surgical equipment. Despite potential cost increases …